Clinical Trial Update: Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa [Phase 3]

View source ↗

Summary

A Phase 3 study evaluated switching between Lamictal immediate-release and extended-release formulations in people with epilepsy. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• LAMICTAL (LAMOTRIGINE)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 3 | Status: COMPLETED